A recent study has identified specific genes that may influence the effectiveness of the anti-smoking drug varenicline in helping individuals quit smoking.

Varenicline, a widely used smoking cessation aid, works by mimicking nicotine and binding to certain proteins in brain cells. This mechanism blocks the pleasurable effects of smoking while reducing cravings. The drug is available under various brand names in India, including Champix.

Researchers from the University of Leicester, UK, revealed that genetic factors might determine how well an individual responds to varenicline. While the drug has been effective for many, it does not work for everyone. The study suggests that understanding genetic influences could help personalize smoking cessation treatments, improving success rates.

The findings could pave the way for more targeted therapies, ensuring that individuals receive the most effective treatment based on their genetic profile.